Needs cold hard facts that cashflow is strong, margins reasonable and prospects are at least goodish. Forget revenue 'pipelines' which are often 'pipedreams'.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025